Sanofi (NASDAQ:SNY) Holdings Raised by Natixis Advisors LLC

Natixis Advisors LLC increased its stake in Sanofi (NASDAQ:SNY) by 4.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,874,193 shares of the company’s stock after purchasing an additional 114,133 shares during the quarter. Natixis Advisors LLC’s holdings in Sanofi were worth $165,640,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. POM Investment Strategies LLC acquired a new position in shares of Sanofi in the second quarter worth about $25,000. Northwest Investment Counselors LLC acquired a new position in Sanofi in the 3rd quarter worth approximately $29,000. Concord Wealth Partners grew its position in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after purchasing an additional 363 shares in the last quarter. Arrow Financial Corp acquired a new stake in Sanofi during the 2nd quarter valued at $35,000. Finally, Fortitude Family Office LLC lifted its holdings in shares of Sanofi by 708.6% in the third quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock valued at $43,000 after purchasing an additional 659 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Price Performance

SNY opened at $47.97 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The stock has a fifty day moving average price of $54.65 and a 200 day moving average price of $52.19. The stock has a market cap of $121.74 billion, a price-to-earnings ratio of 24.47, a PEG ratio of 1.26 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $0.22 by $1.35. The business had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.55 EPS. Analysts forecast that Sanofi will post 4.27 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on SNY shares. Argus lifted their price target on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. Finally, Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.